@Woldanorf I believe thatdata comes from the announcement Positive Datafor RECCE 327 in MRSA Burns Wound Infection (27 November 2019)
I think potentiallyRECCE 327 is “as good” if not better than an already marketed drug (Soframycin) in regards of wound contraction and bacterialload assessment… in an animal model. The upside to 327 is that it isn’t resistantto stronger strains of MRSA.
If its goodenough for three groups of five rats, then I’m excited to see what it will belike in human trials. that data we have to date seems to be highly encouraging
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |